Goals-of-Care & End-of-Life Quality in Relapsed High-Risk Leukemia: Silent Conversations by Graham, Lacy Jo
Pittsburg State University 
Pittsburg State University Digital Commons 
Doctor of Nursing Practice Irene Ransom Bradley School of Nursing 
Spring 2021 
Goals-of-Care & End-of-Life Quality in Relapsed High-Risk 
Leukemia: Silent Conversations 
Lacy Jo Graham 
Pittsburg State University, ljg_aprn@outlook.com 
Follow this and additional works at: https://digitalcommons.pittstate.edu/dnp 
 Part of the Hematology Commons, Nursing Commons, and the Palliative Care Commons 
Recommended Citation 
Graham, Lacy Jo, "Goals-of-Care & End-of-Life Quality in Relapsed High-Risk Leukemia: Silent 
Conversations" (2021). Doctor of Nursing Practice. 48. 
https://digitalcommons.pittstate.edu/dnp/48 
This Scholarly Project is brought to you for free and open access by the Irene Ransom Bradley School of Nursing at 
Pittsburg State University Digital Commons. It has been accepted for inclusion in Doctor of Nursing Practice by an 














GOALS-OF-CARE & END-OF-LIFE QUALITY IN RELAPSED HIGH-RISK 








A Scholarly Project Submitted to the Graduate School 
in partial Fulfillment of the Requirements for the Degree of 




























GOALS-OF-CARE & END-OF-LIFE QUALITY IN RELAPSED HIGH-RISK 
LEUKEMIA: SILENT CONVERSATIONS 
 
 
An Abstract of the Scholarly Project by 
Lacy Jo Graham 
 
 
BACKGROUND: The distorted association of “end of life (EOL)” with “goals of care 
(GOC)” has “silenced” crucial goals discussions in patients with relapsed high-risk 
leukemia, which raises concerns for the provision of care that is inconsistent with 
patient’s values and preferences (Desharnais et al., 2007; Epstein et al., 2016; Gilligan et 
al., 2017; Mack et al., 2010; Piggott et al., 2019; Weeks et al., 2012).       
AIM: The two main goals of this study were to quantify hematologists rate of 
participation in a GOC pathway initiative during two separate months, then explore their 
definition and barriers to having/documenting GOC discussions.   
DESIGN: Mixed-methods, explanatory sequential design (follow-up explanations 
variant).   
SAMPLE: Quan: Hematology inpatient admissions during the months of October 2020 
and January 2021.  Qual: Eighteen leukemia hematologists from one dedicated cancer in 
the United States.  
RESULTS: During the two months, an average of 36% of admissions met criteria for 
GOC pathway initiation, 19% of those had an appropriate initiation order, of which 
15.5% had a properly documented and billed GOC discussion.  Nine hematologists 
responded to the SurveyMonkey with two questions.  All nine included clinical situation 
and communication in their definition/components of GOC discussions.  Time required 
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The consistent provision of high-quality healthcare by Advanced Practice 
Providers (APP) has been clearly established and widely recognized in the literature.  
Initially utilized only in rural, underserved primary care settings, value recognition and 
good outcomes have prompted mass expansion of scope and specialty role opportunity 
for these providers, one such specialty being hematology.  Collectively, APP’s exhibit a 
strong drive to advocate for, influence, and affect high-quality health care through 
leadership, evidence-based practice implementation, and quality improvement projects 
(Sarzynski & Barry, 2019).  A southern California dedicated cancer center and research 
hospital that specializes in hematological malignancies has adopted an inpatient work 
model that requires the APP to routinely work very closely with and collaborate with 
many different hematologists.  A rotating 14-day inpatient rounding schedule requires 
each of 35 hematologists to round only 4-6 weeks/year.  Eighteen of the 33 hematologists 
specialize in leukemia, myelodysplastic syndrome, or other blood disorder and rotate 
through the four leukemia inpatient services.  There are often months between inpatient 
obligations, and for this reason, these physicians rely heavily on APP’s to guide them 
through frequent process and policy changes, quality improvement initiatives, and 




a role of leadership with significant opportunity to observe, analyze, and influence the 
practice habits of physicians.  This role also provides opportunity for the APP to identify 
and address barriers, in order to establish, hone, and strengthen collaborative multi-
disciplinary relationships.   
Clinical Problem/Issue 
In 1997 The Institute of Medicine (IOM) published a report titled “Approaching 
Death: Improving Care at the End of life” that focused on the dying and deaths of adults 
in America.  A pediatric version, “When Children Die: Improving Palliative and End-of-
Life Care for Children and their Families” was published in 2003. In 1999 the IOM 
released Ensuring Quality Care, emphasizing that quality care measurement and 
improvement should not only focus on cancer detection and treatment, but should span 
the entire disease trajectory, including EOL care (as cited in Odejide, 2016).  By 2013, 
impressively, many of the goals articulated in the 1997 report had been achieved, 
including creation of palliative medicine specialty status, increased access to opioids for 
patients with pain, and the widespread adoption of hospital palliative care teams. And yet, 
both in research and in the everyday experience of patients, family members, and 
clinicians, huge gaps remained in the quality of care for the most vulnerable patients. In 
response, the IOM assembled a diverse panel that, in 2014, issued Dying in America: 
Improving Quality and Honoring Individual Preferences Near the End-of-Life.  The 
consensus study report organizes findings across five domains: care delivery, clinician-
patient communication and advance care planning, professional education, policies and 
payment systems, and public education and engagement.  It was discovered that although 




years, the experience for most patients and families still fell short of what ought to be the 
standard. The report also notes that patients nearing the EOL ought to receive treatments 
that match their preferences and goals for care. The last few months of an individual’s 
life is often characterized by frequent hospital admissions, intensive care stays, and 
burdensome transitions across care settings (Tulsky, 2015). A large proportion of deaths 
continue to occur in hospitals and promulgate poor quality EOL care and unsustainable 
costs for the health care system.  The 2014 report provides recommendations for creating 
transformational change in the models of EOL care delivery, clinician-patient 
communication, and advance care planning (as cited in Meghani & Hinds, 2015).   
Quality End-of-Life Care in Hematology 
 The clinical course of hematology-oncology patients differs from patients with 
solid malignancies as these patients are more likely to be admitted and receive life 
sustaining measures near EOL. In a survey conducted among hematologist-oncologists, 
EOL indicators validated for medical oncology patients and considered significant for 
hematology-oncology patients, included not being admitted to intensive care, not being 
intubated or receiving cardiopulmonary resuscitation (CPR) within 30 days of death, not 
receiving chemotherapy within 14 days or a blood transfusion within 7 days of death, and 
dying outside of an acute care unit (Odejide et al, 2016).  The most recent published 
findings of Korsos et al. (2019) demonstrates that having level of intervention 
discussions, palliative care consults and physician/patient established goals of treatment 
may improve EOL quality for patients with hematologic malignancies.   




 Patients with hematologic malignancies often receive aggressive care at the EOL, 
leading to lower quality of life.  While the use of billed palliative care services among 
Medicare beneficiaries with hematologic malignancies has steeply increased in recent 
years, most encounters still occur within days of death in the inpatient setting (Rao, et al, 
2019).  Aggressive EOL care in patients with advanced-stage cancer is increasing despite 
growing concerns that this reflects poor-quality care (Wright et al, 2016).  Furthermore, 
studies have found that, regardless of illness, at least 13% of the time, the EOL care 
provided is inconsistent with the patients’ goals-of-care (GOC) and causes psychosocial 
and financial burden to the family (Khandelwal et al, 2017).  Data regarding this 
phenomenon in hematology specifically, is lacking.      
Goals-of-Care, Palliative Medicine, and End-of-Life Care 
 The GOC conversations may be defined as discussions about prognosis and 
treatment options that clarify patients’ values, goals, and priorities. GOC conversations 
do not routinely occur among patients with advanced cancer, and when they do, it is often 
late in the course of the illness (Childers, 2017).  Ideally, initial, intermediate, and final 
GOC conversations should occur throughout the illness trajectory (Schulman-Green et 
al., 2018).  EOL discussions should be a component of GOC and should be discussed at 
various times throughout the illness.  Integrated palliative care is correlated with earlier 
EOL discussion and improved quality of life (Mack et al., 2012).  National guidelines 
(Ferrell et al., 2018) recommend that discussions about EOL care planning happen early 
for patients with incurable cancer, but, for various reasons, these discussions are still 
occurring within days of death.  Hematologists have specific barriers that interfere with 




EOL discussions in patients with hematologic malignancies.  Early EOL discussions are 
prospectively associated with less aggressive care and greater use of hospice at EOL.  
GOC conversations should promote informed shared decision making by presenting 
accurate prognostic information and treatment options to patients and their families and 
ensure patient/physician concordance of goals is achieved (Mack et al., 2012).  Patients 
with incurable cancer, and those participating in Phase I trials often have misconceptions 
regarding the goals of their treatment regimens (Enzinger et al., 2014).  One study found 
that 69% of patients with lung cancer and 81% of those with colorectal cancer did not 
report understanding that chemotherapy was not at all likely to cure their cancer (Weeks 
et al., 2012). 
Hematologists are Different 
 Historically, hematologists collectively possess certain personality traits, thought 
processes and practice paradigms that result in very specific barriers to having GOC and 
EOL discussions.  Several authors have tried to understand the reason why integrating 
palliative care into hematology is so difficult. Hematologists describe particular issues, 
such as the difficulty for individual prognostication due to the chemo-sensitivity of 
hematological malignancies, and the possibility of allogeneic stem cell transplantation 
that allow ongoing therapeutic goals of curable or long-term survival.  In contrast, acute 
complications are frequent, unpredictable and change the prognosis rapidly (Prod’homme 
et al., 2018).  Often the acute complications may contribute to death before the possible 
involvement of a palliative care team. Furthermore, long relationships that develop 




as addressed to dying patients also contributes barriers for referral (Prod’homme et al., 
2018).   
Having, Documenting, and Billing for Advance Care Planning  
 The barriers to Advance Care Planning in hematologic malignancies exist on 
many levels, are vast, ongoing, and will require system tools, policies, multidisciplinary 
collaboration, and APP leadership to address these quality shortcomings.  Unfortunately, 
as with most issues in healthcare, this is a complex problem with another problem 
uncovered in every solution.  Protocols and policies often are met with opposition and 
slow adoption in a Southern California Cancer research hospital, and despite protocol 
initiation, significant education, and leadership backing on this issue, compliance remains 
low.  Occurrence of GOC and EOL conversations are lacking, documentation of these 
conversations remains low, and Intensive Care Unit (ICU) admission in the last 30 days 
of life remains higher than at similar facilities, despite efforts to address this issue.   
Significance 
Patient and Family 
 Identification of poor prognosis patients, initiating GOC conversations, and 
ensuring proper documentation of these conversations can reduce misaligned treatment 
and patient/family suffering.  Earlier GOC discussions will better prepare the patients for 
the day they are “in a different place” in their illness trajectory.  Discussing EOL when 
they are not near the EOL allows time to explore their goals and share them with their 
family.  Discussing health care wishes with a designated speaker reduces the stress on 




symptom burden may be reduced with earlier palliative care collaboration, and overall 
quality at the EOL will improve for patients (Back et al., 2014).    
Advanced Practice Nurse/Advanced Practice Provider (APP) 
 The emotional burden is globally present in APPs who work in inpatient 
hematology, though it varies in etiology and intensity for many reasons.  The barriers to 
EOL discussions that exist in hematologists are different than those existing in APPs. 
Therefore, APP's often experience emotional distress after witnessing incomplete 
prognostic conversations and excessive offering of treatment that will yield little to no 
benefit.  APP’s see recommendations being made without discussing or considering 
patient goals and are painfully aware of the suffering the patient will certainly endure.  
The level of sharing obtained during the more personable conversations between patients 
and APP’s often uncovers the true misconceptions patients have regarding their 
treatment, prognosis, and chance of meaningful recovery, but hospital culture and their 
role prevents them from exploring these misconceptions and false hopes.  This deeper 
emotional knowledge presents an ethical struggle and can lead to burnout, anxiety, and 
depression (Bourdeanu, 2020).  The unique opportunity the APP has to influence 
physician practice and shift paradigms is significant and should be recognized and 
utilized to generate and disseminate new research and policies pertinent to the practice.    
Specific Aims/Purpose 
 While the global issue discussed is large and multifaceted, any quality 
improvement-research endeavor requires a step-wise approach in which the completion 
of each stage will likely reveal another issue to be addressed in future research.  




Toyoda in the 1930’s revealed the focus of this scholarly project: protocol utilization and 
compliance/non-compliance, and why.  Prior to designing and completing this study, 
hospital leadership had placed the researcher on a task force deemed responsible for 
reducing ICU admissions within 30 days of death in the Southern California Cancer 
Research facility described above.  A hospital based GOC pathway pilot program was 
created and implemented as a potential solution to the fourth “why,” avoidance of GOC 
discussions.  The pathway addresses hematologists evasion of GOC conversations by 
permitting APP initiation of the pathway process using specific criteria to identify and 
refer high-risk/poor-prognosis patients.  Once the referral is made, a social worker 
administers a patient and caregiver support screen (Appendix A), which evaluates 
prognostic understanding.  These results are shared with the inpatient team and primary 
hematologist in a request for a family meeting.   
Shortly after the March 2020 GOC pathway implementation the issue of 
documentation/billing became apparent, and the project objectives were updated.  Even 
when the hematologists were having GOC discussions, they were not documenting them 
in a standardized place or way, and were not billing for their time, making it difficult for 
other providers to access and update.  The objectives of the hospital based GOC pathway 
were modified to the following: 1) Augment GOC pathway project by optimizing the 
primary hematologists’ ease of execution and level of comfort during GOC discussions.  
2) Establish a documentation process that is easily completed and accessed (without 
using the search option or “hunting”) by other providers during subsequent encounters. 3) 
Discover actual and potential APP contribution to the GOC pathway pilot project.  The 




the medical record of GOC.  A metric to be measured, and first purpose of the scholarly 
project was to evaluate the participation of physicians and APPss in the GOC pathway 
process through quantification of patients who met the established “poor-prognosis” 
criteria for pathway initiation, patients with appropriate social work referrals to initiate 
the pathway, and those with a properly documented GOC discussion in the electronic 
medical record during that hospital encounter.  A user-friendly Advance Care Planning 
(ACP) documentation template was created and rolled out one month prior to this inquiry 
into usage.  The second purpose was to gain insight into the hematologists self-reported 
definition of a GOC discussion, the most important components, and their perceived 
barriers.  The goal was to collect and synthesize the candid thoughts, opinions, attitudes, 
beliefs, practice habits, philosophies, perceptions, and comfort level surrounding GOC 
discussions and the proper documentation and billing of these conversations.  Five 
project research questions were constructed to achieve the two purposes.   
Project Questions 
1. How many leukemia inpatients met the established GOC pathway criteria for poor 
prognosis upon admission during the months of October 2020 and January 2021?   
2. How many poor prognosis leukemia inpatients admitted in October 2020 and 
January 2021 had appropriate referral for GOC pathway?   
3. How many poor prognosis leukemia inpatients admitted in October 2020 and 
January 2021 had a properly documented and billed GOC discussion utilizing the 
approved template prior to hospital discharge or death? 
4. How do the hematologists define “GOC conversation” in one sentence and what 




5. What do the hematologists identify as perceived barriers in having/documenting 
GOC conversations?  
Figure 1 
The Five "Whys" 
 
 
GOC pathway participation-DESCRIBE/EXPLAIN WHY or WHY NOT?
Consolidated Framework for 
Implementation Research
Attitude, beliefs, perceived barriers, 
opinions
Quantify number of patients who 1) meet 
criteria, 2) have pathway initiated, 3)have 
properly documented and billed GOC 
Hematologists avoid GOC discussions, no system in place to prompt- WHY?
Creation and initiation of 
GOC Pathway program
Fear of ruining hope, culture
Unaware of documentation 
template
Didn't know they could bill
Time consgtraints, prognostic 
uncertainty, association with 
EOL/DNR
Goal disconcordance, EOL care inconsistent with patient values- WHY?
Hematologists avoid GOC discussions for 
many reasons and there is no 
standardized documentation process
Assumptions by both patients and 
hematologists
Lack of prognostic understanding
Low rates of Palliative and Supportive 
Care Medicine in Hematology
Patients with hematologic malignancies have higher rates of ICU admission in the last 30 days 
of life- WHY?
Lack of goal concordance
Lack of clear goal understanding
Patients often unaware that treatments are 
palliative and not curative
Unrealistic expectations of experimental 
treatment by both patients and 
hematologists
Lower EOL quality in patients with hematologic malignancies-WHY?
Hospital/ICU admissions at 
the EOL
Chemotherapy in the last 14 
days of life
No CPR or Intubation in the 





Definition of Key Terms/Variables 
Advance Care Planning (ACP): a process that supports adults at any age or stage of 
health in understanding and sharing their personal values, life goals, and preferences 
regarding future medical care. The goal of ACP is to help ensure that people receive 
medical care that is consistent with their values, goals, and preferences (Sudore et al., 
2017).  
Advanced Practice Provider (APP): Physician Assistants and nurses who have met 
advanced educational and clinical practice requirements and include Nurse Practitioners 
(NPs), clinical nurse specialists, nurse anesthetists, and nurse midwives (American 
Nurses Association, n.d.). 
Aggressive end-of-life care: ICU admission with or without mechanical ventilation in the 
last 30 days of life, CPR administration in the last 30 days of life, death in ICU.   
Burnout: A state of mental and physical exhaustion caused by one’s job (Freudenberger, 
1974). 
Continuity of Care: Idealized in the patient's experience of a “continuous caring 
relationship” with an identified health care professional (Guilliford et al., 2006). 
Emotional Distress: A highly unpleasant emotional reaction which results from another’s 
conduct (Webster, 2020). 
End-of-Life Care: Care provided to a person with a terminal condition that has become 
advanced, progressive, and/or incurable in the last 30-90 days of life (COH GOC task 
force, 2020).   
Epic: Electronic Medical Record utilized in Southern California cancer research hospital 




Evidence-Based Practice: The conscientious, explicit and judicious use of current best 
evidence in making decisions about the care of the individual patient” is a standard 
definition of Evidence-based Practice (EBP).  Developed by David Sackett, a pioneer in 
EBP, this definition describes integrating individual clinical expertise with the best 
available external clinical evidence from systematic research (Agency for Healthcare 
Research and Quality, 2020). 
Goal Concordance: Care that matches patients’ preferences, enabled by communication 
between clinicians and patients or their surrogates (Sanders et al., 2018). 
Goals of Care (GOC): Derived based upon the patient’s expressed preferences, values, 
needs, concerns and/or desires, may be curative, rehabilitative, life-prolonging, or 
comfort focused (The Joint Commission, 2018). 
Goals-of-Care Discussion/Conversation: The clinician-led discussion, professional 
guidance and support provided to the patient and family intended to result in making 
decisions that reflect the goals and values of the patient.   
Goals-of-Care Pathway: Pathway protocol created by the GOC task force to reduce ICU 
admission in the last 30 days of life that utilizes criteria to identify poor prognosis 
patients and initiate GOC conversations and earlier palliative referral (COH Goals-of-
Care task force, 2020).  
Hematologic Malignancies: Cancers that affect the blood, bone marrow, and lymph 
nodes. This classification includes various types of leukemia (acute lymphocytic (ALL), 
chronic lymphocytic (CLL), acute myeloid (AML), chronic myeloid (CML)), myeloma, 




High-Quality Healthcare: The assessment and provision of effective and safe care, 
reflected in a culture of excellence, resulting in the attainment of optimal or desired 
health (Allen-Duck et al., 2017). 
Life-Sustaining Measures: Interventions aimed to prolong length of life through 
mechanical and pharmacological means, Cardio-Pulmonary Resuscitation, endotracheal 
intubation, renal replacement therapy, vasopressor blood pressure support (Zhang et al., 
2009).  
Palliative and Supportive Care Medicine (PCM, SCM or PSCM): Care given to 
improve the quality of life of patients who have a serious or life-threatening disease. The 
goal of supportive care is to prevent or treat as early as possible the symptoms of a 
disease, side effects caused by treatment of a disease, and psychological, social, and 
spiritual problems related to a disease or its treatment (Hui et al., 2015). 
Poor-Prognosis Patient: Relapsed or refractory Acute Myeloid and Acute lymphoblastic 
leukemia after 1 line of therapy; Lymphoma or Myeloma with disease progression after 
at least two prior lines of therapy; exclusions: admission for curative intent treatment (i.e. 
allogeneic hematopoietic stem cell transplant or cellular therapy in a relapsed or 
refractory patient) (COH GOC task force, 2020). 
Prognostication: A prediction of future medical outcomes of a treatment or a disease 
course based on medical knowledge (Sinclair, 2007 as cited in Medscape, 2007) 
Theoretical Framework 
The Consolidated Framework for Implementation Research (CFIR) is a useful 
tool for guiding rapid-cycle evaluation of the implementation of practice transformation 




meaningful change in the healthcare delivery system.  Some estimates indicate that up to 
two-thirds of organizations’ efforts to implement change, fail (Burnes, 2004).  Without 
adaptation, interventions usually come to a setting as a poor fit, resisted by individuals 
who will be affected by the intervention, and requiring an active process to engage 
individuals in order to accomplish implementation.  During implementation, it is 
important to monitor progress for unanticipated influences (barriers and facilitators) and 
progress toward implementation goals (Damschroder et al., 2009).   
The CFIR will serve as a roadmap for pathway project evaluation and data 
gathered in this study will provide valuable information to fill in existing gaps in 
knowledge of the 5 domains of the CFIR.  The CFIR comprises five major domains (the 
intervention, inner and outer setting, the individuals involved, and the process by which 
implementation is accomplished, see Figure 2), each of which will be examined to 






Consolidated Framework for Implementation Research 5 Domains 
 
In addition to the CFIR, Rogers (1962) Diffusion of Innovation Theory (see 
Figure 3) contributed to the theoretical framework of the project goals and design.  The 
researcher recognized the potential ability of APP leadership in diffusion of innovation as 
a respected opinion leader, change agent, and champion within the institutional social 
system.  The doctorly prepared APP has both the skill and a unique advantage in leading 
change by exercising his/her role as an innovator and early adopter to positively influence 













Diffusion of Innovation Model 
 
Logic Model 
A logic model (see Figure 4) assists in brainstorming and planning for the project 
and project needs.  Mapping resources, activities and outputs provides a platform for 
project initiation to be added to as the project develops.  Objectives, including short, 
medium, and long-term outcome measures (see Figure 5) will guide project evaluation at 


























Describe the phenomenon 
of hematologist aversion to 
GOC discussions
Determine levels of 
compliance/non-compliance 
with GOC pathway initiation
Explore hematologists 
attitudes, beliefs, and 










Establish expertise of 
process.
Acquire knowledge and data 
Critical analysis
Recognition and planning 
for future initiatives
Outputs
Quantitative and qualitative 
data
Meaningful depiction of 
barriers to GOC pathway
Personalized interventions 






Quantify the number of patients 
who meet GOC pathway criteria 
in 2 seperate months.
Quantify appropriate  pathway 
initiation and completion of MD  
documentation/billing in poor 
prognosis patients.
Compile the hematologists 
personal perceived barriers in 
having/documenting GOC 
discussions. 
Obtain and compile the 
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Analyze qualitative data for 
patterns and themes specific to 
this set of Hematologis.
Interpret and organize findings. 
Share the findings with 
hematologists, Nurse 
Practitioners, and GOC task 
force.




G Use findings to address specific 
concerns and create 
educational interventions for 
this group of physicians.
Expansion of program to 
outpatient setting.
Reduction of ICU admissions in 
the last 30 days of life
Enhance and align hematologist 
understanding of the GOC 
pathway and the intended 
outcomes of the project.
Improve goal-concordant care 


















 A search of the literature was conducted on Google Scholar.  Using the advanced 
search function produced 129 articles that had been published since 2016, 43 articles 
since 2019, and 21 articles since 2020, with all of the words: aggressive end-of-life care, 
quality goals-of-care discussion, with the exact phrase: quality end-of-life care, with at 
least one of the words: hematology hematologist “hematologic malignancies” 
“hematologic malignancy” “blood cancer” leukemia lymphoma myeloma, and without 
the words: pediatric.  The forty-three articles since 2019 were examined for themes and 
relevance to the project, then narrowed again to articles without the words: Korean 
Brazil, which was the maximum number of characters allowed in that search criteria box.  
Further application of exclusion criteria performed through personal review of the 35 
remaining articles.  Three articles containing “Norway” “Thai” and “Lebanese” were 
excluded, one feasibility study was excluded, and 19 documents that pertained to 
oncology as a whole or other disease process, were excluded.  The 12 remaining articles 
were extensively reviewed to extrapolate important topics, data, concepts, and themes.  
Additional articles utilized were found through reference-mining, the “cited by” and 




from the original 12 articles in Google Scholar, CINHAL, Summons, PubMed, and : end-
of-life; goals-of-care; hematology; hemato-oncology; blood cancer; advanced cancer; 
aggressive end-of-life care; quality, barriers and facilitators of end-of-life; goals-of-care 
conversations, discussions; patient-provider communication; prognostication; prognostic 
understanding; advance care planning; decision-making; process conversation analysis; 
palliative care; goal-concordance; patient- hematologist discordance; hospice; ICU at 
EOL; bereaved family member perceptions.  One hundred thirty-one items are cited in 
this literature review.   
History of Dying 
Prior to the 20th century, the family commonly provided EOL care at home with 
the assistance of visiting health care professionals.  In the United States, death at home in 
the care of family has been widely superseded by an institutional, professional, and 
technological process of dying. This technological process has detached the EOL from 
the rest of living (Field & Cassel., 1997).  Dr. Cecily Saunders started the modern EOL 
movement by establishing the first formal hospice program at St. Christopher's in 1967 
(Liegner, 1975). In the same period, Dr. Elizabeth Kubler-Ross sought to understand the 
psyche of the dying patient by describing the psychological stages of dying. She also 
advocated home, rather than the intensive care unit, as the place of “good death” (Kubler-
Ross, 1969).  In 1990, Congress passed the Self-Determination Act, which required 
healthcare providers to inquire, inform, and assist patients regarding advance directives.  





Unfortunately, despite widespread education and effort, one study in 2010 showed 
that, only 26.3% of surveyed adults 18 and older had an advance directive. The most 
frequently reported reason for not having one was lack of awareness (Rao et al., 2014).  
Another study examined 6,122 Health and Retirement Study (HRS) patients, age 60 and 
older, who died between 2000 and 2010.  In 2017, a systematic review of 150 articles 
published in the period of 2011-2016 was performed in order to determine the proportion 
of United States adults with a completed living will, health care power of attorney, or 
both.  Among the 795,909 people in the 150 studies that were analyzed, 36.7 % had 
completed an advance directive, including 29.3 % with living wills. These proportions 
were similar across other years reviewed. Similar proportions of patients with chronic 
illnesses (38.2 %) and healthy adults (32.7 %) had completed advance directives (Yadav 
et al., 2017). A descriptive study of 50 inpatients with high-risk leukemia defined 
“complete advance care planning documentation” as in-chart documentation of surrogate 
decision maker plus either a written advance directive or documented GOC discussions, 
and found that despite very poor prognosis, only 24% of patients had complete advance 
care planning documentation in their chart, and only one-third had specific components 
of advance care planning addressed. This study was the first study to characterize access 
to palliative care and advance care planning by focusing on this high-risk population of 
patients with hematologic malignancy and adds to a small but growing body of evidence 
showing that patients with varied hematologic malignancies are less likely to have access 
to elements of palliative care and advance care planning than patients with solid tumors 




Kim et al. (2020) explored agreement in EOL treatment wishes in patient-
caregiver dyads of patients with hematologic malignancies to find modifiable factors 
associated with completion of advance treatment directives.  The study found significant 
patient-caregiver discordance in treatment wishes regarding CPR, ventilator support, 
hemodialysis, and hospice, and noted knowledge about advance directives as the 
modifiable factor significantly associated with the completion of an advance directive 
(Kim et al., 2020).  A study examining 206 patient/oncologist dyads found a majority of 
oncologists (76.7%) did not correctly identify GOC that they believed their patients 
wanted, indicating they did not fully understand their patients’ GOC, even at the last 
meeting prior to death (Douglas et al., 2019).  This raises concern that in these cases, 
patients are less likely to receive care consistent with their preferences (Desharnais et al., 
2007; Epstein et al., 2016; Gilligan et al., 2017; Mack et al., 2010; Piggott et al., 2019; 
Weeks et al., 2012).   
Quality End-of-life Care 
There is a growing amount of substantiated concern regarding the widespread 
provision of non-beneficial, aggressive interventions and costly over-treatment in the 
United States at the EOL (Cardona-Morrell et al., 2016; Institute of Medicine, 2015; Lyu 
et al., 2017; Mohammed at al., 2019).  Treating hospital patients who are on an EOL 
trajectory in the same way as those who have a reversible cause for their illness is not 
only futile, but also a costly and wasteful form of preventable harm in healthcare (Carter 
et al., 2017; Farrell et al., 2008; Smith et al., 2013; Zhang et al., 2009).  Still, the 
aggressive treatment for terminal advanced cancer patients at the EOL is a common 




changed markedly since the Institute of Medicine (IOM) published Approaching Death: 
Improving Care at the End of life (1997), however, both research and the everyday 
experience of patients, family members, and clinicians suggest that huge gaps remain in 
the quality of care for the most vulnerable patients. This poor care continues against a 
backdrop of rising health care costs and a sense that patients who account for the greatest 
percentage of this expenditure do not benefit from, and may even be harmed by, it's 
excess.  The report urges a patient-centered and family-oriented approach to EOL care 
that honors individual preferences as a national priority and emphasizes the needs for 
improved communication about EOL preferences between clinicians and patients (IOM, 
2015).   
In 2003, Earl et al. generated the earliest set of EOL quality measures for patients 
with advanced cancer.  These measures, focused on the potential overuse of intensive 
care at the EOL and the underuse of hospice services, are now endorsed by national 
organizations such as American Society of Clinical Oncology (ASCO) and the National 
Quality Forum (NQF) (ASCO Practice Central, n.d; Earle et al., 2004; Earle et al., 2005; 
Earl et al., 2008; Grunfeld et al., 2006.; NQF, n.d.).  The eight quality measures are as 
follows: Hospice >7 days before death; no chemotherapy <14 days before death; no ICU 
admission in the last 30 days of life; fewer than two hospitalizations in the last 30 days of 
life; fewer than two Emergency Department visits in the last 30 days of life; no intubation 
in the last 30 days of life; no CPR in the last 30 days of life; and not dying in an acute 
care facility.  These measures were later deemed highly acceptable in a large national 
cohort of hematologic oncologists and no additional hematologic specific measures were 




measures for suitability in hematology was determined after several years of data 
collection revealed significantly more intensive EOL cancer-directed care (eg. higher 
rates of ICU admission in the last 30 days of life, lower rates of hospice enrollment, 
fewer days on hospice, and higher rates of chemotherapy close to death) in patients with 
hematologic malignancies than in those with solid tumor cancers, suggesting suboptimal 
EOL care for this patient population (Earl et al., 2008; Fletcher et al., 2016; Ho et al., 
2011; Howell et al., 2011; Hui et al., 2014; LeBlanc et al., 2015; O’Connor et al., 2014).  
The number of days spent at home has been suggested as a potential novel, patient-driven 
indicator of quality EOL (Andersen et al., 2019Groff et al., 2016).  A large population-
based analysis of 11,127 patients in Ontario, Canada who died from hematologic 
malignancies between 2005-2013, found that while over 80% of patients spend greater 
than 120 of their last 180 days at home, those with acute leukemias spent the fewest at 
home (Cheung et al., 2019)  
The benefits of hospice care at the EOL are well established in patients with solid 
tumor malignancy and have been shown to improve quality of life for patients and 
families, as well as improve family perceptions of quality EOL care and minimize, 
psychological distress, risk for depression and post-traumatic stress for the bereaved 
(Teno & Curtis, 2016; Wright et al., 2008; Wright et al., 2010) .  Barriers to timely 
hospice referral and quality EOL care in patients with hematological malignancies 
include transfusion dependence, the potential for “cure” despite advanced disease, 
uncertainty regarding prognosis, and concerns about affecting patients’ hope, among 
other things.  Early palliative referral, much like hospice, comes with a stigma in 




(Hui et al., 2015; LeBlanc et al., 2018; Odejide et al., 2016; Odejide & Steensma, 2020).  
In the absence of subspecialty referral, evidence has found linking a high level of primary 
palliative care (defined as palliative care delivered by the primary transplant/leukemia 
physicians) through GOC discussions and/or advance care planning, with high-quality 
EOL care outcomes, often with concurrent disease-directed therapy (Lin et al., 2019). 
Aggressive End-of-life Care 
 Adult intensive care unit (ICU) utilization is common near the EOL.  In the 
United States, approximately 40% of patients die in the hospital, and nearly 60% of these 
deaths occur after admission to the ICU, that is, 1 in 5, or 20% of Americans die while 
utilizing ICU care (Angus et al., 2004; Seferian & Afessa, 2006).  A recent population-
based surveillance, epidemiology, and end results-Medicare database set examined 
Medicare beneficiaries who died of hematologic malignancies in 2008-2015 and found 
that 33% died in an acute hospital setting, and 36.8% had an intensive care unit 
admission in the last 30 days of life or died in the ICU (Egan et al., 2020).  There has 
been considerable advancement towards patient-centered EOL care in the United States, 
but the EOL needs in hematology are unique and make transitions in care settings 
challenging.  The labor-intensive level of care needed at the end of the disease trajectory 
is often beyond the physical and emotional capability of family members, who are often 
unprepared and lack the resources necessary to care for someone in that capacity 
(Verhoef et al., 2020).  Even so, patients and families consistently designate home as the 
preferred place of death, but instead, more often die in the acute care setting following 
escalating intervention (Chino et al., 2019; Howell et al., 2010; Maddocks et al., 1994; 




EOL ICU admissions in patients with cancer may be justified to manage 
potentially reversible disorders in some patients, however, a significant number of these 
admissions are potentially inappropriate, as about half of the ICU admissions for patients 
with cancer result in death (Bosslet et al., 2015; Kress et al., 1999; Thiery et al., 2005; 
Weir et al., 2014).  Despite remarkable treatment advances, many hematological 
malignancies remain incurable, have unpredictable/uncertain trajectories, and have highly 
variably outcomes, which can be particularly poor for some karyotypic subtypes.  
Deterioration is often sudden and unexpected, manifesting as relapse or a devastating 
failure to respond to one or more lines of intense standard of care chemotherapy regimens 
(Roman et al., 2016; Smith et al., 2015; Swerdlow et al., 2016).  Moreover, patients with 
hematological malignancies are often treated with multiple new, experimental, and 
intense antineoplastic regimens with significant or unknown toxicities, and those 
treatments may continue until the last days of life (Hui et al., 2010; Hui et al., 2013; 
Sanchez-Cuervo et al., 2020).  Clinical trial participation is significantly associated with 
aggressive EOL care, intensive care unit death, and inferior quality of life near death 
(Enzinger et al., 2014).  Understandably, these patients and their caregivers frequently 
experience psychological distress (Bishop et al., 2007; Rodin et al., 2013). 
Caregivers often indicate dissatisfaction with the care provided to their loved ones 
at the EOL.  Shirai et al (2016) published the first quantitative study evaluating care for 
myelodysplastic syndrome/leukemia and lymphoma patients during their last 
hospitalization.  They found that 57% of caregivers were not satisfied with the care 
provided and a “good death” was often not achieved (Shirai et al., 2016).  A similar 




service Medicare who died of lung or colorectal cancer, and linked perception of better 
EOL care to earlier hospice enrollment, avoidance of ICU admissions within 30 days of 
death, and death occurring outside the hospital (Wright et al., 2016), while another study 
found that one in 8, or 13% of bereaved family members report that care in the last month 
of life was not consistent with the decedent’s wishes (Khandelwal et al., 2017).  
McCaughan et al. (2019) examined preferred place of care and death in patients with 
blood cancers from the perspectives of bereaved relatives and found that, while home is 
overwhelmingly the preferred place of death, the hospital was sometimes preferred and, 
on reflection, some relatives identified this as the “right” place for the patient to have 
died. Factors impacting achievements of home death where disease characteristics, the 
occurrence and timing of EOL discussions, family networks and resource availability. 
Early, honest and realistic communication of risk and uncertainty, initiated by 
hematologist, could prevent over-optimism and facilitate advanced planning among 
patients and relatives, as well as allow primary care staff adequate time to prepare for the 
patient’s potential death at home.  
Patient-Clinician Communication 
 The Institute of Medicine’s (IOM) 2015 report on approaching death called for a 
transformation in how we care for the dying in this country, emphasizing the need for 
improved communication about EOL preferences between clinicians and patients (IOM, 
2015). Improved health care communication has been associated with improvements in 
many different objective and subjective health outcomes, including blood pressure 
control, hemoglobin A1C and diabetes, adherence to medication use, and patient 




Zachariae et al., 2003; Zolnierek & Dimatteo, 2009). Communication in oncology 
practice presents numerous challenges and although studies show that most patients want 
their oncologists to discuss EOL plans, these conversations often do not occur (Barakat et 
al., 2013; Mack et al., 2010; Wright et al., 2008).  Healthcare providers often do not 
discuss GOC with seriously ill hospitalized patients (Anderson et al., 2011; Hofmann et 
al., 1997) or they approach them inadequately (Deep et al., 2008; Osborn et al., 2012), 
contributing to provision of high intensity care in the final months of life, even when 
patients and caregivers prefer treatments focused on comfort and quality of life 
(Covinsky et al., 2000; Heyland et al., 2006; Wenger et al., 2000; Yuen et al., 2011). 
Mounting evidence suggests that aggressive EOL cancer care is a modifiable 
trend, and that earlier discussions between patients and their physicians regarding EOL 
preferences could be associated with less aggressive and less costly care near death 
(Mack et al., 2012; Roman et al., 2019; Starr et al., 2019; Wright et al., 2008; Wright et 
al., 2010; Weeks et al., 1998; Prigerson, 1991).  In 2017, The American Society of 
Clinical Oncology (ASCO) released consensus guidelines regarding patient-clinician 
communication with recommendations that addressed specific topics, such as discussion 
of GOC and prognosis, treatment selection, and EOL care in addition to providing 
guidance regarding core communication skills and tasks that apply across the continuum 
of cancer care (Gilligan et al., 2017).   
 Barriers to GOC and EOL discussions in oncology are widely acknowledged and 
researched, they include but aren’t limited to unrealistic patient expectations, clinician 
concern about taking away hope, and unrealistic clinician expectations (Odejide et al., 




lack of understanding or omission of information by their providers.  In addition, GOC 
are too often not addressed for patients at high risk of death (El-Jawahri et al., 2017).  
Patients with metastatic solid tumors typically have a more indolent course of progression 
compared to patients with hematologic malignancies, and one study found only 4% of 
patients with hematologic malignancies (vs 23.5% of solid tumor patients) had discussed 
GOC or code status within the last month before their terminal ICU admission (Heng et 
al., 2020).    
Several researchers agree that hematologists possess certain personality traits and 
practice paradigms that yield very specific barriers to having GOC and EOL discussions 
that are not fully understood, and that research on this phenomenon is needed.  
Prod’homme et al (2018) recently published a qualitative grounded theory study using 
individual interviews to give rare insight into these hematologist-specific barriers.  
Hematologists describe particular issues, such as the difficulty for individual 
prognostication due to the chemo-sensitivity of hematological malignancies, and the 
possibility of allogeneic stem cell transplantation that allow ongoing therapeutic goals of 
curable or long-term survival. In contrast, acute complications are frequent, unpredictable 
and change the prognosis rapidly.  Often the acute complications may contribute to death 
before the possible involvement of a palliative care team. Furthermore, long relationships 
develop between patients and their hematologists, and the negative representation of 
palliative care contributes to lack of referral (Gatta & LeBlanc, 2020).  Prod’homme et 
al.’s (2018) study uses qualitative grounded theory and individual interviews to identify 
barriers and explore ten hematologists’ thought logic.  The qualitative analysis found 




hematologist’s desire to help patients fight-for-life, the hematologist’s own perception of 
what is good for patients, and the hematologist’s difficulty with incertitude (Prod’homme 
et al., 2018).  Additionally, issues with accurate prognostication in the era of exceptional 
responders, patient prognostic understanding, discordant GOC, and identification of when 
EOL begins, have been described (Odejide et al., 2014; LeBlanc et al., 2018; Loh et al., 
2019).  
Fight-for-Life  
 Prod’homme et al. (2018) recognize that Hematologists’ view talking about death 
as stressful, difficult, and taboo in a recent study.  The 2018 study found that physicians 
often adopt a false positive attitude with their patients in order to avoid the subject of 
death.  They do this by leavings things unsaid, being ambiguous, and omitting certain 
information. According to them, in the event of recurrence, their responsibility is to 
reassure their patient with a positive attitude, re-inspire the confidence that was lost when 
the disease recurred, and provide motivation; this role was not felt to be compatible with 
conducting an EOL discussion.  As long as hematologists have therapeutic options to 
treat blood-related cancer, they seem unable to open discussions about EOL.  Some 
believe imminent death is proof of professional failure, and fear things such as loss of 
credibility, jeopardizing patient compliance or patient-physician relationship, and 
potential negative effect on treatment success and tolerance (Prod’homme et al., 2018).  
Hematologists own Perceptions of What is Good for Patients 
 The willingness of hematologists to consider patient perspectives for the future 
and talk about EOL is restricted by their desire to maintain patient-physician relationship 




discussion was an explicit request coming from the patient. Even then, the hematologists 
aimed to provide a certain degree of psychological security for the patient, and endorsed 
probing to see what the patient wants, leaving the door open to conversations, and testing 
the patient to see whether or not they really wanted to receive an answer.  They seek to 
protect their patients from violent and EOL discussions at the time of recurrence, and 
often representations of what they feel is best for the patient is defined according to the 
hematologist’s own ideals about health care and EOL (Prod’homme et al., 2018).  An 
example of this issue is often seen at diagnosis of acute myeloid leukemia (AML).  
Hematologists know that understanding the biology of AML has led to therapeutic 
interventions potentiating meaningful responses with more acceptable toxicity profiles 
compared with intensive therapy.  Nevertheless, the diagnosis often comes late in life 
when patients are more likely to have impaired functional status and suffer from other 
comorbid illnesses. Therefore, the oncologist must be unbiased and fully engaged with 
the patient, discussing goals of therapy and EOL issues, in a shared decision-making 
process (Leblanc & Erba, 2019). 
Difficulty with Incertitude, Hope, and Clinical Trial Participation 
 For hematologists, having and EOL discussions and collaborating with palliative 
care teams is equivalent to affirming that the outcome is inevitably fatal, and therefore 
incompatible with hope.  Certainty of imminent death is the preferred incentive for EOL 
discussion.  Incertitude and hope of remission, however slight, stops any discussion about 
the threat of death or advance care planning (Prod’homme et al., 2018). 
For patients with advanced refractory cancer, experimental therapy, particularly 




Although the principle purpose of clinical trials is to generate knowledge to improve 
future therapy, many patients incorrectly believe that the primary purpose is to directly 
benefit participants (Joffe & Weeks, 2002; Peppercorn et al., 2004). Classic Phase I trials 
are designed with nontherapeutic primary aims of determining toxicity and the optimal 
dose for subsequent testing and infrequently provide direct benefit (Horstmann et al., 
2005; Roberts et al., 2004).  Unfortunately, most patients misunderstand the purpose of 
early phase trials, and enroll anticipating a substantial likelihood of personal benefit, even 
cure, rather than for altruistic reasons (Daugherty et al., 1995; Meropol et al., 2003; 
Nurgat et al., 2005; Sulmasy et al., 2010; Truong et al., 2011; Weinfurt et al., 2003; 
Weinfurt et al., 2008).  Nevertheless, several highly successful early-phase trials 
involving targeted cancer therapies demonstrated that drugs in early development can 
occasionally provide significant benefit to patient-subjects (Flaherty et al., 2010; Kwak et 
al., 2010; Topalian et al., 2012).   
Many patients with very limited life expectancy are highly motivated to continue 
disease-directed treatment and pursuing investigational therapy may help them and their 
loved ones feel they have fought their best fight, thereby finding greater acceptance and 
peace at the EOL (Agrawal et al., 2006) Conversely, trial participation might distract 
some patients from coming to terms with death and making EOL plans.  National 
guidelines support balancing hope and desire for more treatment with other EOL GOC, 
including symptom control, avoiding futile interventions, and supporting the patient's 
ability to come to terms with and prepare for death (Peppercorn et al., 2011; Steinhauser 




Accurate Prognostication in the Era of Exceptional Responders, Prognostic 
Understanding, and Discordance in Perceived Chance of Cure 
 Understanding one's prognosis is fundamental to making informed treatment 
decisions.   Novel immunotherapies and genome-targeted treatments, which yield 
exceptional responses and a small proportion of patients, further complicates 
hematologists’ ability to formulate and communicate prognosis to patients with advanced 
disease. Existing approaches to improving patient clinician communication in 
hematology are inadequate to accommodate different levels of skill and aptitude among 
practicing hematologists (LeBlanc et al., 2018).  One study found that over 90% of 
hematologists report initiation of prognostic discussions at diagnosis, but only 17.7% 
readdressed prognosis until death was imminent (Habib et al., 2019).  If, by chance, a 
hematologist is able to articulate accurate prognostication, often time patients report an 
inaccurate perception of their prognosis. Prior studies have demonstrated that up to 82% 
of patients with hematologic malignancies have a different understanding of their 
prognosis compared with their hematologist (El-Jawahri et al., 2015; El-Jawahri et al., 
2019: Lee et al., 2001; Sekeres et al., 2004).  Much of this discordance is skewed toward 
optimism, meaning that patients tend to have higher expectations for cure, which has 
significant implications for care received.   The discordance may be related to patient, 
physician, and/or societal factors, but the optimism motivates patients to opt for more 
aggressive care (Chen et al., 2017; Chochinov et al., 2000; Derry et al., 2019; Gramling 
et al., 2016; Henselmans et al., 2017; Loh et al., 2019; Mack et al., 2015; Robinson et al., 




The availability of novel, efficacious treatments is changing the landscape of 
cancer therapeutics and dramatically improving prognosis in a subset of patients with 
advanced disease. As hematologists, it is gratifying and exciting to administer therapies 
such as immune checkpoint inhibitors to patients who previously had a prognosis of less 
than one year, and occasionally to see their cancer remain quiescent for many years 
(Wolchok et al., 2017).  Unfortunately, many patients do not respond to immunotherapy, 
have underlying health conditions, or experience toxicities that prohibit administration.  
The availability of these novel therapies is making the already significant problem of 
communicating prognosis more complex (Elias, 2019; LeBlanc et al., 2018).   
Identification of When End of Life Begins 
 The studies raising concerns about the quality of EOL care for patients with blood 
cancers provide little insight into the associated perceptions and decision-making 
processes of the hematologic oncologists involved in their care.  In addition, little is 
known about how to define the “EOL phase” for these patients.  Participants in four focus 
groups from the Dana Farber/ Harvard Cancer Center indicated that identifying when the 
EOL phase of blood cancer begins is challenging (Odejide et al., 2014). Uncertainty 
regarding prognostication centered on several factors. First, providers for patients with 
leukemia, lymphoma, and hematopoietic stem cell transplantation specified that 
possibility of cure for many hematologic malignancies, even in relapse states, makes it 
difficult to prospectively determine when the EOL phase of disease begins. This was 
specifically noted as a salient difference between blood cancers and the majority of 
advanced (Stage IV) solid malignancies, which are incurable. As one participant 




Whereas with lymphoma although most patients with refractory disease will likely die, 
we all know there is a tail...through allotransplant” (Odejide et al., 2014 p. e398). 
Participants agreed that although the median survival for many hematologic malignancies 
may not differ from advanced solid malignancies, the potential for cure, even when small, 
impacts their ability to accurately determine when a patient is at the EOL (Odejide et al., 
2014).  For this reason, interdisciplinary cooperation, timely discussions about specialist 
palliative referral, and indicators to ‘flag' patients in need of specialist or primary 
palliative care are important, but they are largely missing and further models of early 
integrated palliative care should be evaluated in prospective studies, and established in 
daily clinical practice (Oechsle, 2019). 
Summary 
 While the research has described several EOL quality indicators, in order to affect 
change, one must intervene with specific interventions that aggressively address one issue 
at a time. Administrative and stakeholder input have focused this researchers’ effort on 
reducing ICU admission in the last 30 days of life and EOL healthcare costs, while 
increasing the quality of EOL care provided in a tertiary inpatient hematological research 
facility. While researching and synthesizing the available information, the root cause of 
aggressive EOL care has been identified and described in this literature review, leading to 
establishment of potential interventions to address existing gaps and shortcomings in 
common practice, namely, having and documenting earlier GOC and EOL discussions in 




















 Practice problems are often large, polymorphic, system-wide issues with unclear 
solutions.  For this reason, a mixed-method study that examined the discussion and 
documentation compliance rates while also exploring perceived barriers in cases of non-
compliance provided benefits drawn from the potential strengths of both quantitative and 
qualitative methods.  Mixed-methods research enabled the researcher to explore diverse 
perspectives and uncover relationships that exist between the intricate layers of the multi-
faceted research questions.  The purposeful mixing of methods in data collection, 
analysis, and interpretation of evidence fostered data linkage and integration between 
rates of pathway utilization and perceived barriers, therefore enabling a panoramic view 
of the research problem.   
Benchmark data shows that patients with hematologic malignancies receive more 
aggressive care at the EOL and have higher rates of ICU admission in the last thirty days 
of life, which is associated with poor quality EOL care (Wright et al, 2016).  A task force 
convened to address this issue and created a GOC pathway that could endorse goal 
concordance.  The rollout of the project was poor, uncommunicated, and did not utilize 




the project came as a surprise both to hematologists and inpatient APP’s, who were not 
educated on the importance or reasoning behind the new pathway.    
Project Design 
 This study sought to answer five research questions: 
1. How many leukemia inpatients met the established GOC pathway criteria for poor 
prognosis upon admission during the months of October 2020 and January 2021?   
2. How many poor prognosis leukemia inpatients admitted in October 2020 and 
January 2021 had appropriate referral for GOC pathway?   
3. How many poor prognosis leukemia inpatients admitted in October 2020 and 
January 2021 had a properly documented and billed GOC discussion utilizing the 
approved template prior to hospital discharge or death? 
4. How do the hematologists define “GOC conversation” in one sentence and what 
do they consider the most important components?   
5. What do the hematologists identify as perceived barriers in having/documenting 
GOC conversations?  
It was suspected that compliance with the GOC pathway was low, which indicated 
the need for evaluation and adaptation.  The CFIR will serve as a roadmap for pathway 
project evaluation and data gathered in this study will provide valuable information to fill 
in existing gaps in knowledge of the 5 domains of the CFIR.  These gaps are italicized in 





Consolidated Framework for Implementation Research 
  
• Intervention source- Negative perceptions regarding 
development and legitimacy exist.
• Evidence Strength and Quality-Negative belief that the 
intervention will have desired outcomes.
• Relative advantage- Perspectives regarding the advantage 






• Patient need is present and proven.  GOC conversations are 
not being had and prognostic discordance exists.  
• Peer Pressure- competition to remain "the best in the west."
• Governmental and external mandates, recommendations, 
tuidelines, pay-per-performance, benchmark reporting.  
Outter Setting
• Difference in opinion and vision of various hematologists
• Poor communication vs too much communication 
impersonal (Zoom) communication.
• Collaboration and open feedback
• Culture, norms, values, and basic assumptions
• Implementation climate- capacity for change, shared 
receptivity of involved individuals to the intervention. 
Prioirity, incentive, readiness.
Inner Setting
• Knowledge, skill, beliefs, opinions, experiences of 
individuals.
• Attitude and value placed on GOC discussions.
• Individual belief in their own capabilities, self-efficacy.
• Hematologist stage in progression toward sustained 







• Executing- Quality of execution
• Reflecting and evaluating- QUANTITATIVE AND 
QUALITATIVE FEEDBACK ABOUT THE PROGRESS 







This study used a mixed-methods, explanatory sequential design (follow-up 
explanations variant) to explore the phenomena of hematologists’ aversion towards GOC 
conversations in the inpatient setting.  This study design provided a more comprehensive, 
in depth understanding of the practice problem and resulted in a framework of evidence 
to be used in project implementation evaluation.  All qualitative data was obtained using 
an anonymous SurveyMonkey platform to promote participation.   
Once the project was approved for exempt status by both the facility’s IRB and 
the academic institution, retrospective chart review by the researcher first quantified the 
degree of compliance that currently existed in referral of criteria-specified poor-prognosis 
patients for goals discussions via the GOC pathway, and hematologist compliance in 
having/documenting/billing for goals discussions in these patients.  Percentages from the 
facility in which the hematologists practice described the issue as it pertains to them more 
than nation-wide percentages that are published.  Compliance was not monitored or 
manipulated in real-time or influenced by the researcher.  However, the researcher 
remained an established resource if the hematologist chose to reach out and request 
assistance or guidance.  The quantitative data answering research questions 1, 2 and 3 
was initially intended to be included in the letter to the hematologists containing the 
Survey Monkey link requesting qualitative answers to research questions 4 and 5, 
however, after reviewing the data, it was decided that inclusion of this information may 
discourage truthful response to the survey questions.    
Sample/Target Population 
 The study was designed with an identical mixed-method sampling design because 




component was to offer detail and elaboration about phenomena that was captured 
quantitatively.  Recruitment for the study consisted of the eighteen hematologists 
practicing in a southern California dedicated cancer research center, that specializes in 
hematology, largely leukemia, and other diseases that may be cured with allogeneic 
hematopoietic stem cell transplant.  These eighteen hematologists rotate through four 
leukemia services on a two-week rotation schedule.  Permission was received from both 
the institution’s IRB and the academic entity’s IRB.  Participation in survey completion 
was anonymous and voluntary.   
The pathway was created to initiate GOC conversations between hematologists and 
patients with a poor prognosis based on the following criteria: 
1) Leukemia/ myelodysplastic syndrome (MDS) with relapsed or refractory disease 
after one line of treatment.   
2) Multiple myeloma or lymphoma with relapsed or refractory disease after two 
lines of treatment.  
3) Excluding those admitted for a potentially curative treatment such as allogeneic 
stem cell transplant, chimeric antigen receptor T-cell therapy (CAR-T) and 
autologous transplant.   
The study sought to explore leukemia physicians, therefore, only patients 
identified by the first criteria were initially considered for inclusion in the quantitative 
data collection.  However, in response to an administrative request to the task-force, all 
inpatient admissions meeting either criteria were included in the quantitative results.   




treatment such as hematopoietic stem cell transplant, and those admitted to receive 
treatment under some specific IRB protocols with targeted therapies, and CAR-T.   
Inclusion & Exclusion Criteria.  Only the eighteen hematologists at this facility 
who specialized in leukemia and rotated through the four leukemia services were 
included in the qualitative arm of this study.  No lymphoma, myeloma physicians or 
APPs were asked to participate.     
Ethics and Protection of Human Subjects.  Prior to data collection, approval 
was obtained from the Pittsburg State University Irene Bradley School of Nursing 
Institutional Review Committee and the dedicated cancer center’s IRB.  The proposed 
quantitative research involved retrospective chart review of all patients admitted to the 
hematology service during the months of October 2020 and January 2021, involved no 
procedures for which written consent is normally required outside of the research context, 
and the research presented no more than minimal risk of harm to subjects.    
The researcher initially applied for expedited IRB approval by submitting the 
Expedited Review of Research Involving Human Subjects Criteria Form, The 
Application for Approval of Investigations Involving Human Subjects, and the 
Application for Waiver of Informed Consent Form to the Pittsburg State University 
Office of Graduate and Continuing Studies and the Pittsburg State University Committee 
for the Protection of Human Research Subjects (CPHRS), after these documents 
underwent review and were approved by the Pittsburg State University Irene Ransom 
Bradley School of Nursing.  The request was modified to exempt after receiving exempt 
approval from the cancer institution’s IRB.  Participation in the qualitative 




to the leukemia division three days prior to sending the official study request with IRB 
approved consent, cover letter, and survey link.  The purpose of the study, voluntary 
nature of the study, and intended use of the information received was again explained, 
along with the steps taken to protect respondent anonymity, in the official study request 
e-mail containing the consent and link to the survey.  The responses were kept 
anonymous in the survey monkey and the researcher did not share login or password to 
their account containing the survey results.   
Biases.  Biases are a potential barrier in any qualitative exploration of human 
feelings.  Even though anonymity was practically guaranteed, there was still a risk that, 
consciously or subconsciously, the hematologists would distort their responses to present 
themselves in the best light or simply because they were unaware of their own behavior 
and biases.   
Instruments   
 The quantitative data was obtained with retrospective chart review by the 
researcher.  Information was entered into an Excel document consisting of columns: 
Admit Date, Service, Admitted for, Meets criteria (Y/N), Why?, SW Consult placed 
(Y/N), Consult date, Location at time of consult, Meeting occurred (Y/N), Proper 
documentation of GOC meeting under ACP notes using approved template (Y/N), ACP 
charge present during admission (Y/N) , and an opt-out criteria/ Misc extra information 
column for notes the researcher considered potentially useful in analyzing and 
understanding the problems surrounding GOC discussions.   The spreadsheet was later 
condensed for ease of analysis and the why, consult date, location at time of consult, and 




stored on facility locked computer in the approved OneCloud drive for Business under 
the researcher’s institutional account.  The Doctor of Nursing Practice (DNP) student 
researcher is employed by the facility, has access to the charts and no HIPPA violations 
took place.  The patient MRN was the only identifier and only identifiable by a current 
employee with Epic access, however, under the recommendation of the facility’s IRB, the 
MRN was removed from the data collection spreadsheet prior to saving the document 
each time it was accessed.    
 The qualitative instrument was a survey (Appendix C), hosted by 
SurveyMonkey.com and consisted of two exploratory open-ended questions aimed to 
provoke deep thought and explore the personal opinions and beliefs of the hematologists 
in an anonymous form.  Content validity was established after review from institutional 
APP and MD leadership, and scholarly project committee, consisting of two doctorly 
prepared APP’s and a statistician.  The hematologists were informed of the DNP 
researcher’s intent to publicize the de-identified qualitative findings in fulfillment of the 
DNP scholarly project, and that the information would be used to modify the current 
protocol at their facility based on what was learned.    
Procedure and Implementation Plan 
 After project approval was obtained from both academic and research facility 
IRB, retrospective chart review was performed on each patient admitted to the 
Hematology and Hematology Transplant Readmit services during the months of October 
2020 and January 2021.  The charts were personally accessed by the DNP student 
researcher, who is an employee of the site facility. The history and physical were first 




Patients who were admitted to one of the leukemia services and identified as poor 
prognosis by the first criteria stated above, underwent further chart review to determine 
presence of correct social work order to initiate GOC pathway, presence/absence of 
properly documented GOC conversation, and advanced care planning charge using CPT 
code 99497 or 99498.  The DNP student researcher worked closely with social worker 
who tracked the presence or absence of GOC meetings in all inpatients who had the GOC 
pathway initiated via social work order.  The social worker’s data was compared against 
the researchers data to verify consistency and validity of certain research findings. An 
Excel spreadsheet (described above) was stored on the secure institutional OneDrive for 
Business, which is the institutional-wide approved storage cloud that allows the safe 
construction, storage, sharing, and editing of documents that may contain confidential 
patient information.  Once all patient charts admitted during the two-month time frame 
were examined and findings placed in excel, assistance was solicited from a colleague 
experience in Excel to guide in utilization of Excel features for data extrapolation and 
analysis.  Additional assistance was provided through program help functions and videos.  
Figure 7 illustrates the final collection method of extrapolated data. 
Figure 7 













……… Y/N Y/N Y/N Y/N Y/N 
  
Though originally intended to be included with the cover letter, the researcher 




completion.  It was thought the results may be threatening to the hematologists as they 
indicated very poor compliance with the pathway and GOC initiative.  It was shared that 
the information obtained would be used to develop strategies to address the well-known 
aversion to GOC conversations in hematology.  The survey was kept open for ten days 
and reminder e-mails containing the survey link were sent out every 3 days and on the 
day of survey closing.  The service line director offered to “nudge” the hematologists, but 
the researcher declined their offer to protect the integrity of the responses.  Ten days after 
the initial e-mail, the survey closed.  Then, extrapolation and analysis of the qualitative 
data began with the assistance of a PhD prepared NP, a statistician, a DNP mentor, and 
other experts.       
Consent was assumed with completion of the survey though a very detailed 
institutional consent form was required by the facility’s IRB.  It was assumed that each 
hematologist would be ethical and complete the survey only one time, and do so honestly    
During the planning process, the researcher considered the limitations within the 
sample population concerning generalizability, however, it was the intent of the 
researcher to limit the findings to this specific population in order to obtain meaningful 
data that could be used to construct tailored solutions.  Also, due to the known 
phenomenological aversion of hematologists to GOC discussions, there was a concern 
that there may be a lack of response to the survey.     
Treatment of Data/Outcomes/Evaluation Plan 
Analysis of Data.  This was an explanatory sequential design research study, and 
the integration intent was to connect the results and provide a strong explanation for the 




to analyze and report the quantitative data obtained from chart review and report level of 
compliance or non-compliance.  The inductive qualitative analysis used tags and content 
analysis to identify themes and categories for each of the open-ended questions of the 
survey so that an in-depth understanding of the phenomenon could be learned.  
Evaluation Measures.  Outcome and evaluation measures were correlated with 
the project research questions, objectives established in the logic model (see Figure 4) 
and goals established in the short, medium and long-term outcomes (see Figure 5).  The 
survey instrument was intended to provoke thoughtful, meaningful responses in a non-
threatening and anonymous form.  Project quality was based on criteria for doing high-
quality mixed methods research, as proposed in many frameworks in Fabregues and 
Molina-Azorin’s (2017) review.  The study met the following five criteria: 
1. A strong rationale existed for collecting and analyzing both quantitative and 
qualitative data. 
2. The quantitative and qualitative strands were well implemented and adhere to 
the quality criteria of each tradition.   
3. The quantitative and qualitative components of the study were well integrated. 
4. The sampling, data collection, and data analysis procedures for both strands 
were linked to the study intent and the research questions. 
5. Inferences were consistent with the study findings and with the study intent.         
Plan for Sustainability 
 In 1987, the United Nations General Assembly issued the report of the world 
Commission on Environment and Development. The report described sustainability as 




their own needs, considering social and economic resources in addition to natural 
resources.”  Healthcare in its current state in America is not sustainable at this point and 
change needs to occur.  This research project was developed to contribute, in part, to 
healthcare sustainability by reducing the unwanted and unnecessary use of medical 
resources that is currently straining our system.  By establishing clear goals based on 
prognostic understanding, patients and providers with goal concordance can make shared 
decisions that reflect the patient’s values, beliefs and desires, especially at the EOL, 
which is when a person typically uses the most health care resources.  Both political and 
financial components necessitate sustainability of this, and other projects aimed at 



















 Patients with hematologic malignancies often receive aggressive care at the EOL, 
leading to lower quality of life.  Aggressive EOL care in patients with advanced-stage 
cancer is increasing despite growing concerns that this reflects poor-quality care (Wright 
et al, 2016).  Furthermore, studies have found that, regardless of illness, at least 13% of 
the time, the EOL care provided is inconsistent with the patients’ GOC and causes 
psychosocial and financial burden to the family (Khandelwal et al, 2017).   
In April of 2020, a freestanding U.S. academic cancer hospital launched a pilot 
GOC pathway project ultimately aimed at improving goal concordant care.  The pathway 
identifies “poor prognosis” patients admitted to the hospital based on hematologic 
disease-specific criteria.  The original task force did not include APP leadership or 
representation during the planning phase, which resulted in an unsuccessful first roll-out.  
Fortunately, a DNP student leader saw this as an opportunity to prove APP input as a 
necessity for program success.  The project objectives were modified to include “discover 
actual and potential NP contribution to the GOC pathway pilot project” and, after weeks 
of multi-disciplinary collaboration, the pathway pilot was re-launched with several 




The Alliance of Dedicated Cancer Centers (ADCC) represents the ten 
freestanding U.S. academic cancer hospitals, and this alliance developed a national 
implementation   initiative to enhance goal-concordant care for patients with cancer.  The 
initiative recognizes and embraces the vision that all patients with cancer and their 
families should receive care that aligns with their values and unique priorities.  In 
September 2020, the ADCC released the Improving Goal Concordant Care (IGCC) 
Initiative Implementation Planning Guide, which was created to address system gaps in 
the centers and to establish new expectations for when and how GOC conversations 
occur.  This placed the DNP student researcher and the GOC pathway project at the 
center of the institution’s plan for a nationwide quality improvement initiative.   
When rolling out a practice changing initiative, it is important to monitor progress 
for unanticipated influences (barriers and facilitators) and progress toward 
implementation goals (Damschroder et al., 2009).  The implementation of this practice 
transformation initiative needed to be evaluated.  The CFIR is the theoretical framework 
that was chosen to serve as a roadmap for pathway project evaluation and the data 
gathered in this study provided valuable information to fill existing gaps in the 
knowledge of the 5 domains of the CFIR.   
Purpose 
 The first purpose of this scholarly project was to evaluate participation of APPs 
and physicians in the GOC pathway process and using a quantitative method of study. 
The second purpose used a qualitative study design to explore hematologists’ self-reports 
regarding their knowledge, opinions and barriers surrounding GOC discussions and the 





1. How many leukemia inpatients met the established GOC pathway criteria for poor 
prognosis upon admission during the months of October 2020 and January 2021?   
2. How many poor prognosis leukemia inpatients admitted in October 2020 and 
January 2021 had appropriate referral for GOC pathway?   
3. How many poor prognosis leukemia inpatients admitted in October 2020 and 
January 2021 had a properly documented and billed GOC discussion utilizing the 
approved template prior to hospital discharge or death? 
4. How do the hematologists define “GOC conversation” in one sentence and what 
do they consider the most important components?   
5. What do the hematologists identify as perceived barriers in having/documenting 
GOC conversations?  
Quantitative Sample/Results 
 The first 3 project questions were answered with quantitative examination of data 
that was obtained via chart review of the inpatient admissions for October 2020 and 
January 2021 (see Table 1).  For both months, only patients admitted to the Hematology 
Transplant Readmit or Hematology service were eligible for inclusion.  Admissions to 
the Bone Marrow Transplant (BMT), breast, colorectal, endocrinology, Emergency 
Treatment Center (ETC), extended recovery, gastroenterology, gynecologic oncology, 
integrated care services, internal medicine, interventional radiology, medical oncology, 
neurosurgery, oncology, orthopedics, otolaryngology head and neck, PED transplant, 
pediatric transplant readmit, pediatrics, plastic surgery, surgery, surgical oncology, 




Table 1  





1. How many leukemia inpatients met the established GOC 
pathway criteria for poor prognosis upon admission during the 
months of October 2020 and January 2021?   
 
63 68 
2. How many poor prognosis leukemia inpatients admitted in 
October 2020 and January 2021 had appropriate referral for 
GOC pathway?   
 
19 10 
3. How many poor prognosis leukemia inpatients admitted in 
October 2020 and January 2021 had a properly documented and 
billed GOC conversations utilizing the approved template prior 





The Tableau Dashboard in Epic was used to sort the patients by month of 
admission and service.  For the month of October 2020, each of the 721 total admissions 
were reviewed, 623 were inpatient admissions and 98 were observation.  At the time of 
the initial access and chart review, 206 patients were admitted as an inpatient to either the 
Hematology service or the Hem Transplant Readmit service, and 8 patients were 
admitted to these services under observation during the month of October 2020.  Of these 
206 admissions, 4 Kaiser admissions, 1 Coronavirus-19 (COVID) admission, and 8 CAR-
T admissions were excluded.  Of 193 eligible encounters, 63 (33%) patients met criteria 





October 2020 Admissions Data 
 
  Of the 63 patients who met criteria for initiation of the GOC pathway, 19 had an 
appropriate social work consult to initiate the pathway and 4 of those had appropriate 
documentation and billing for a GOC discussion by the physician.  Of the 44 patients 
without appropriate consults placed, 2 eventually had consults upon ICU admission via 
the ICU pathway and one had a supportive care medicine consult.  Forty-one patients 
who met criteria did not have a social work order or a documented GOC discussion at 
any point during that admission encounter (Figure 9). 
CAR-T, 8, 4%
COVID, 1, 0%
KAISER, 4, 2% Did not Meet 
Criteria, 130, 67%
















October 2020 Admissions Meeting GOC Pathway Criteria 
 
January 2021 
 In January 2021, 230 patients were admitted as an inpatient to the Hematology 
service or the Hem Transplant Readmit service.  Excluding the 11 CAR-T admissions, 3 
Kaiser admissions and 40 COVID admissions, 176 admission encounters were eligible 
for inclusion in this study. Sixty-eight (39%) patients met the criteria for initiation of the 
GOC pathway and 108 (61%) did not (Figure 10). 













63 Encounters Met Criteria Did not have Consult
ICU/SCM Pathway






January 2021 Admissions Data 
 
 
Of the 68 encounters that met criteria for GOC pathway initiation, 10 (15%) had a 
social work order placed to initiate the pathway.  Fifty-three (78%) did not have an order 
or documented discussion at all, and 5 (7%) had an order placed upon ICU admission via 
the ICU GOC pathway.  Of the 10 encounters with appropriately placed pathway orders, 
9 (90%) had no Advance Care Planning documentation and no Advance Care Planning 
(99497 or 99498) charge during that admission and only 1 (10%) had an appropriately 
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 Project questions 3 and 4 required a descriptive qualitative inductive design that 
utilized content and thematic analysis of data that was obtained via an anonymous 
SurveyMonkey survey with two open ended questions (see Appendix C).  The 
anonymous survey link was sent to all 18 hematologists in the leukemia division and was 
open for 10 days.  Nine hematologists (50%) responded to the survey with 100% 
completion of both questions.  The average time spent completing the survey was five 
minutes.   
Content analysis of each question began with examination of each response and 
assigning various tags using the tag tool in the SurveyMonkey student package.  
Thematic analysis of the tags was completed with the assistance of a Doctor of 




No ACP note or 
charge, 9, 90%
Proper Note/Charge,          
1, 10%




68 Encounters Met Criteria Did not have Consult
ICU/SCM Pathway





Philosophy (PhD) NP and themes were identified.  The tags/themes were then 
independently reviewed by a DNP, a master’s prepared supportive care NP, two 
supportive care physicians and one hematologist.  The word cloud feature, which finds 
common words that are used most often in the responses, was not useful in analyzing the 
content. 
Question #1  
 The purpose of the first question was to explore the hematologists’ definitions of 
and key components of GOC conversations in one or two sentences.  
 Twenty-two tags were created from the 9 answers and assigned appropriately to 
each response (Figure 12).  The number of tags assigned to each question ranged from 5 
to 9, the average being 6.3.  
Figure 12 
































Clinical situation and communication were the two dominating themes and 
present in 100% of the responses, in some form.  From these, six sub-themes emerged 
with further thematic analysis, each containing 2-5 of the tagged categories (see Table 2). 
Table 2 










Options/Treatment/Strategies Plan for tx 
Hope for tx 
Clinical trial 
(end) Hospice, DNR, CC 
Side effects/Complications 
Outcomes Expected outcomes-PT 
Expected outcomes-MD 
Best/Worst case scenario 
Understanding Mutual Understanding 
Patient Understanding 
Decision Making Joint Decisions 
Alignment 
Patient Values/Wishes 
Concept Clarifying what GOC means to the patient. 
Dynamic 
Not hospice, DNR, Comfort Car 
     
Question #2 
 The purpose of the second question was to gain insight into the hematologists’ 
perceived barriers to having/documenting GOC conversations in the inpatient setting.  
Barriers may include thoughts surrounding prognostication, culture, effect on hope, 




 Seventeen tags were created and appropriately assigned to each of the nine 
responses.  The number of tags for each response ranged from 2 to 5, the average being 
2.8 (see Figure 13).  Five themes emerged, each containing 2 to 5 tagged sub-themes (see 
Table 3).  
Figure 13 





























Timing/Location Emergency/unexpected change in patient condition 
Timing/patient condition; goal is cure 
Location- Clinic setting is best. 
Difficult to coordinate 
Personal/behavioral Avoidance 
Difficult/Depressing/Unpleasant 
Worried about effect on hope/never give up culture. 
Ownership by primary hematologist 
Prognostic uncertainty 
Patient Unrealistic expectations 
Never give up attitude* 
Cultural issues 
Discussion Skills required. 
Too much time/don’t have time 
Inconsistent messages to the patient 
Concept Global misunderstanding of what GOC discussions are 
Wrong association with EOL/DNR (when typical goal is cure) 
 
Outcomes and Objectives 
Short-Term Outcomes    
Four short term outcomes that were evaluated were appropriately achieved with 
the research questions (see Table 4). 
Table 4 
Short-Term Outcomes 
Short-term Outcome  Met  Research Question 
Quantify the number of 
patients who meet 
GOC pathway criteria 
in 2 separate months 
Y 1. How many leukemia inpatients met the established 
GOC pathway criteria for poor prognosis upon 
admission during the months of October 2020 and 






pathway initiation and 
completion of MD 
documentation/billing 
in poor prognosis 
patients. 
Y 2. How many poor prognosis leukemia inpatients 
admitted in October 2020 and January 2021 had 
appropriate referral for GOC pathway?   
3. How many poor prognosis leukemia inpatients 
admitted in October 2020 and January 2021 had a 
properly documented and billed GOC conversations 
utilizing the approved template prior to hospital 
discharge or death? 
 
Obtain and compile the 
hematologists personal 
definition of a GOC 
discussion 
Y 4. How do the hematologists define “GOC 
conversation” in one sentence? 
Compile the 
hematologists personal 
perceived barriers in 
having/documenting 
GOC discussions 
Y 5. What do the hematologists identify as perceived 








Medium-term Outcome  Met  Method 
Analyze qualitative data 
for patterns and themes 
specific to this set of 
hematologists  
Y Qualitative analysis of SurveyMonkey findings. 
 
Interpret and organize 
findings 
Y Completion of chapters 1-5 of Scholarly project  
 
Share the findings with 
hematologists, APPss, 
and GOC task force 
IP Some quantitative data has been shared with the task 
force.  All findings will be shared at project 
completion.  
Submit findings for 
publication. 
F The DNP student researcher plans to submit the 
findings for publication in a peer-reviewed journal 
upon completion.   





 In the future, the study will need to be evaluated for success against 5 long-term 
outcomes (see Table 6). 
Table 6 
Long-Term Outcomes 
Long-term Outcome Plan 
Use findings to address specific concerns 
and create educational interventions for 
this group of physicians. 
 
Plug data into the CFIR, which will be 
used by the task force to aid in 
implementation success. 
Expand the GOC pathway program to the 
outpatient setting. 
DNP researcher will identify an outpatient 
NP “owner” and invite them to join the 
task force to create outpatient roll-out 
plan. 
Enhance and align hematologist 
understanding of the GOC pathway and 
the intended outcomes of the project.   
Presentation of results and ongoing NP 
involvement in the project, serving as a 
resource and liaison between 
administration and physicians. 
Improve Goal Concordant Care in High-
risk leukemia patients. 
Align with the ADCC’s recommendations 
and participation in the Improving Goal 
Concordant Care Initiative. 
 
Summary  
This study had two explicit purposes, which were appropriately achieved through 
the chosen methodology.  The first purpose, to evaluate participation of APPss and 
physicians in the GOC pathway process, was achieved through chart review and 
quantitative analysis of the discovered data.  The second purpose, to elicit hematologists’ 
definitions of a GOC discussion and perceived barriers to having/documenting GOC 
discussions, was achieved through qualitative analysis of anonymous survey data.  To 
provide a broader picture, instead of analyzing the data from two consecutive months, the 




inpatient admissions meeting the specified criteria was similar (33%, 39%) between the 
two months; however, the number of appropriate referrals (23%, 15%) and 
documented/billed GOC discussions (21%, 1%) was higher in October than in January.  
The reasons for the decline are unknown and further research inquiry is needed to explore 


















 The general purpose of nursing research is to answer relevant questions and solve 
problems in nursing practice (Polit & Beck, 2021).  Research purposes and specific study 
goals can range along a descriptive/explanatory continuum, but a fundamental distinction 
separates the studies that aim to describe phenomena and those that are cause-probing 
(Polit & Beck, 2021).  This study had two explicit purposes, which were appropriately 
achieved through this mixed-methods study. 
The global, over-reaching purpose of this research was to improve EOL quality in 
hematology patients by reducing the number of patients who experienced ICU admission 
in the last 30 days of life.  The focus of this research was to evaluate a program that was 
created in response to a nation-wide request for a solution to this problem.  The 
theoretical framework (CFIR) and study purposes were determined by utilizing the 5 
“whys” to transform a very large, complex, intimidating problem into a smaller, 
manageable, less intimidating problem that could be addressed in a single study.  Though 
the effectiveness of this root cause analysis (RCA) tool has been questioned periodically 
for assuming the existence of only linear failures (Latino, 2015), the 5 “whys” was easily 
modified by the researcher (see Figure 1) to acknowledge the divergent causes of each 




appropriate topics for future research.  Addressing the 5th “why” in a single study 
required a mixed-methods design with two purposes, each lying on opposite ends of the 
descriptive/explanatory continuum.  Quantifying the number of admitted patients who 
met GOC pathway criteria and comparing that number to the number of referrals and 
appropriately documented/billed GOC discussions effectively described the lack of 
program participation amongst the providers, and qualitative exploration sought to 
explain and understand why this lack of participation exists.    
Relationship of Outcomes to Research 
Translating Evidence, Planned Change, and Project Implementation Evaluation 
Using evidence in practice is a complex process that requires more than a 
practitioner’s ability to critically appraise evidence and make rational decisions.  The 
implementation of evidence-based practice depends on the achievement of significant and 
planned change involving individuals, teams, and organizations (Rycroft-Malone & 
Bucknall, 2010).  Many research-proven interventions fail to translate into meaningful 
change in the healthcare delivery system; some estimates indicate that up to two-thirds of 
organizations’ efforts to implement change fail (Burnes, 2004).   
In October 2020, only 6% of patients who met criteria for pathway initiation had a 
properly documented/billed goals discussion in their electronic medical record at the time 
of data collection; that number further declined to 1% in January 2021.  In 2017 Keith et 
al suggested utilization of a structured model to aid in rapid-cycle evaluation of practice 
transformation initiatives.   In 2009, Damschroder et al. made recommendations for 
successful program implementation after their study found that success is more likely 




progress toward implementation goals.  Logically, one could infer that the inverse is true, 
and that failure is more likely when the implementation plan does not monitor progress 
for unanticipated influences (barriers and facilitators) and progress toward 
implementation goals.   The decline in program participation occurred in the absence of a 
theoretically based implementation evaluation plan, which inversely supports 
Damschroeder et al’s (2009) findings.    
The Problem of Aversion 
The phenomenon of hematologist aversion to EOL discussions and poorer EOL 
quality in hematology is well documented, as is the increased discordance regarding 
prognosis, treatment goals, and EOL preferences between hematologists and their 
patients (Earl et al., 2008; Fletcher et al., 2016; Ho et al., 2011; Howell et al., 2011; Hui 
et al., 2014; LeBlanc et al., 2015; O’Connor et al., 2014).  This study found that up to 
90% of inpatient admissions meeting criteria for GOC discussions via GOC pathway 
lacked documentation/billing of these discussions in their electronic medical record.  
While this does not prove a pattern of patient/provider misalignment regarding prognosis, 
treatment, EOL preferences, or goal discordance, it does support an aversion to GOC 
discussions amongst leukemia hematologists in addition to the heavily researched 
aversion to EOL discussions. (Howell et al., 2011, Prod’homme et al., 2018, Ojejide et 
al., 2014).  This research offers a very new and small window of insight into why this 
suggested pattern of discussion aversion exists despite the growing body of evidence 
supporting the want, need, and absence of these crucial discussions in patients with 
hematologic malignancies (Bernacki, 2015). 




The concept of GOC is historically ambiguous and inconsistent between providers 
(Brandt et al., 2012).  In 2016, Susan Stanek sought to clarify the concept of GOC using 
Norris’s method of concept clarification to create an operational definition.  She reports 
three key findings: 1) GOC are the established, agreed on, desired health expectations 
that are appropriate, documented and communicated. 2) GOC are formulated through the 
thoughtful interaction between a human being seeking medical care and the healthcare 
team.  3) Patients, members of the healthcare team and the healthcare system when GOC 
are established.  There is no mention of EOL or death in her (Stanek, 2016) definition.  
Perception and stigma remain an issue in the hematology setting.   
As shown in much of the previous research on the subject, existence of a 
stigmatic association of “GOC” with “EOL” (Corbett et al., 2013; Ganguli et al., 2016; 
Piggott et al., 2019) is evident in this study sample. Some of the hematologists described 
the conceptual barriers of themselves and their peers surrounding the GOC discussion, 
while others described their barriers based on their own misconceptions (Table 7).  Many 
of the same barriers exist for GOC discussions in these hematologists as Prod’homme et 
al (2018) described as barriers to EOL discussions, which increasingly demonstrates the 












Self-Aware “One barrier to GOC discussions is that both physicians and patients 
typically associate them with EOL discussions.”   
 
“Misunderstanding of the GOC discussions among many people 
involved- including health care professionals and patient/families.” 
 
“The GOC discussion has nothing to do with ‘not escalating their 
medical care’ or ‘nothing to offer,’ or ‘you have a poor prognosis and 
there is no or little hope’.” 
 
“The GOC discussions and more specific management items such as 
code status/comfort care, etc. need to be de-coupled.” 
Unaware “GOC discussions are sometimes difficult and depressing.” 
 
“It is unpleasant to deliver bad news.” 
 
“Effect on hope” 
 
“The typical goal is cure in patients with hematologic malignancies.” 
 
“Cultural issues, which make talking about death taboo” 
 
Prognosis 
It has been shown that hematology patients are more likely to experience ICU 
admission in the last 30 days of life, which contributes to poor EOL quality, and that 
earlier and better GOC discussions increase EOL quality and goal concordance between 
clinicians and their patients (Mack et al., 2012; Roman et al., 2019; Starr et al., 2019; 
Wright et al., 2008; Wright et al., 2010; Weeks et al., 1998; Prigerston, 1991). Through a 
survey, Habib et al (2019) found that the majority of hematologists reported discussing 
prognosis with their patients at diagnosis, yet even though prognosis evolves during the 




patient, or only doing so near death.  Therefore, nearly four out of five (80%) 
hematologists do not readdress prognosis throughout the disease trajectory, hence 
engaging in “silent GOC discussions” that do not contain current, factual prognostic 
information.  The quantitative lack of documented goals discussions containing 
prognostic information found in this inquiry may support this finding; however, a 
prognostic qualitative theme emerged as many of the hematologists define the 
components of a goals discussion and describe their barriers.  The silent conversations are 









“A meeting to align patient goals with provider understanding of 
prognosis.” 
 
“To carry with the patient a conversation to educate them about… 
prognosis and understand their wishes in regards to what's important 
to them” 
 
“Diagnosis, prognosis, options for treatment, clinical trials, back-up 
plan.” 
 
“A careful discussion…prognosis, clinical situation and what the 
patient’s objectives are given the reality of the situation.” 
2-Barriers “It’s hard to assess impact of treatment that may impact 
prognosis/outcomes of survival” 
 
“Sometimes lack of all information needed to accurately determine 
prognosis.” 
 
“Physicians often prognosticate based on unrealistic expectations 
regarding the likelihood of good outcomes in the face of recurrent 
disease”  




Barriers to Goals-of-Care Discussions in Hematology 
 Previous research has explored barriers to EOL discussions hematology and GOC 
discussions in medical oncology.  To date, there is no research focused on GOC 
discussions in hematology. Piggott et al. (2019) surveyed and reported barriers to GOC 
discussions from the perspective of medical oncology practitioners and found that 
participants perceived patient and family member factors as the most important barriers 
to GOC discussions.  These included family members’ difficulties accepting a poor 
prognosis, lack of family agreement in the GOC, difficulty understanding the limitations 
of life-sustaining treatments, lack of patients’ capacity to make GOC decisions, and 
language barriers.  Patient and family factors were not identified as a theme in 
hematologist perceived barriers to GOC discussions.  Both the 2019 study and this study 
did find lack of time to be a perceived barrier to GOC discussions (Table 9). 
Table 9 












“Usually takes one hour or more.” 
 
“Number of eligible patients might exceed the time capacity that one 







 The evolving role of APP as influencers and crucial components in the health care 
system is increasingly recognized as these professionals continue to expand and display 
their knowledge (Kilpatrick et al., 2011).  In this study setting, the unique professional 
relationship between hematology Medical Doctor (MD) and APP creates a captive MD 
audience for which the APP should utilize to affect evidence-based practice change 
interventions by influencing, educating, and guiding the physician's practice when a 
change from the “old ways” is necessary.  In most settings, the value of the APP is 
recognized by the supervising physician and is respected and appreciated (Trautmann et 
al., 2015). The evolution of advanced practice into what it is today can be fully attributed 
to many years of thoughtful motivation and a united vision of practicing to the highest 
extent of one’s knowledge and ability (Hanson & Hamric, 2003).   
Initially, this study aimed to further explore and explain hematologist’s barriers to 
having/documenting GOC discussions. The quantitative inquiry was designed to describe 
physician compliance in GOC pathway completion, however, during data collection, the 
role of the APP in physician non-compliance became apparent.  While physician barriers 
must be explored, it became increasingly evident that APP barriers to implementation 
initiatives must also be explored in future research. To compare the number of poor 
prognosis patients identified to the number who had properly documented/billed goals 
discussions would create an unfair disadvantage to the hematologists.  The number of 
pathway initiations by the APP/GOC meeting requests needed to be compared to the 
number of documented/billed discussions to more clearly understand the issues at hand.  




initiatives further supports the power of APP presence and leadership in the successful 
implementation of initiatives.    
Evaluation of Theoretical Framework 
 The CFIR was chosen as a theoretical framework to evaluate the progress of 
program implementation of the GOC pathway an independent dedicated cancer center in 
Southern California. The framework was chosen because of the apparent generalizability 
of the model, which was constructed based on analysis of 19 implementation research 
models (Damschroder et al., 2009).  Since the 2009 publication, the Consolidated 
Framework for Advancing Implementation Science has been cited in numerous 
publications, all of which support the successful utilization of the framework for 
implementing hospital-based practice change.  A 2015 study (Breimaier et al.) found the 
CFIR a valuable and helpful framework for: 1) Assessment of the baseline process and 
final state of the implementation process and influential factors. 2) The content analysis 
of qualitative data collected throughout the implementation process. 3) Explaining the 
main findings.  Also, in 2015, the generic implementation framework was published, and 
was based on the 5 domains of the CFIR (Moullin et al., 2015).  In Keith, Crosson et al’s 
(2017) study using the CFIR across 21 primary care practices participating in the 
comprehensive primary care initiative, results showed that utilizing the CFIR to guide 
data collection, coding, analysis, and reporting of findings supported a systematic, 
comprehensive, and timely understanding of barriers and facilitators to practice 
transformation. Their approach to using the CFIR produced actionable findings for 
improving implementation effectiveness during the initiative and for identifying 




Throughout this research process, many theoretical frameworks were seen in the 
literature, but, because of the generalizability and adaptability of the CFIR to almost any 
setting, it is still thought to be the most appropriate model for this project.   
Evaluation of Logic Model 
 The logic model chosen (Figure 3) was appropriate and clearly stated the 
objectives, resources, activities, and outputs. The objectives were related to the short, 
medium, and long-term outcomes and were achieved through the activities and outputs. 
Cited resources plus additional resources obtained throughout the process were also 
utilized to reach the objectives. The simplicity of the logic model made it the most 
appropriate for this project as it was easy to read and gave a clear roadmap of the project 
aims.   
Limitations 
The primary limitation of this study lies within the research topic itself, GOC.  
There is an overall lack of interest in GOC, which was noted in the mere 50% survey 
response rate.  The novice level of experience possessed by the principal researcher may 
also be a limitation.  The sample size may be considered a limitation as well as the 50% 
response rate to the survey.  Several known limitations were recognized as assumptions 
early in the research process.  It was an assumption that each hematologist would answer 
the survey only once and do so truthfully.  However, the anonymous survey link sent via 
e-mail was not designed to limit the response to one per person, but instead it was 
designed to promote easy access and maintain anonymity.  The quantitative chart review 
method presented limitations due to human error and processing since each chart was 




researcher’s interpretation of the information in the patient’s electronic medical record.  
Also, the study was completed during the COVID-19 pandemic and visitors/family 
members were not allowed in the facility, therefore, GOC meetings had to take place via 
Zoom or other remote communication method.  The anxiety of learning to live with 
COVID-19 fears and the changes it brought upon may have caused additional aversion to 
GOC discussions in hematologists.   
Instrument Limitations 
Due to the anonymous survey study design, the responses lacked the advantage of 
verbal conversation and back-and-forth interaction that takes place with personal 
interview methods of qualitative discovery.  It was impossible to ask for clarification of 
thoughts or ideas, the interpretation was determined by the health care professionals who 
examined the data.  Prod’homme et al.’s (2018) study used personal interview of ten 
hematologists to explore the barriers to EOL discussions when potentially fatal 
hematological malignancies recur, and this study sought to similarly describe barriers to 
GOC discussions in patients with relapsed high-risk leukemia.  The anonymous survey 
instrument was chosen because it was thought to be the most likely method to 
successfully collect the candid opinions/thoughts of at least fifteen hematologists, but the 
low response rate collected the thoughts of only nine hematologists.  Also, the instrument 
demanded interest and effort on the part of the respondent, whereas personal interview 
could be considered less effort for the hematologist.  The hematologists who already 
possess some level of interest in improving GOC discussions at the facility are likely the 
ones who took the time to thoughtfully respond to the survey.  It is likely that the 




strong disinterest in of the subject that would deter them from participating in the survey.  
Also, due to the anonymous survey design, it was an assumption that each hematologist 
would truthfully respond to the survey questions one time, and that the survey link would 
not be shared with anyone else who may access and complete the survey.  The self-
reported nature of the survey also presented an opening for the hematologists to distort 
their responses or behavior to present themselves in the best light, based on unawareness 
of self-behavior.  The intent was to use open-ended, broad questions that did not lead the 
respondent in their response; however, the inclusion of examples in question #2 may have 
led or guided response to the survey and caused data collection biases. 
Sample Limitations  
The original intended sample size of 20 hematologists was reduced to 18 due to 
one hematologist retiring and one leaving the practice.  Neither physician had been 
replaced when the survey was opened.  The time, or perceived burden of time, required to 
complete a survey could have played a role in the choice not to complete the survey.  
This study as well as any study that qualitatively examines hematologists and GOC will 
likely contain a bias towards those who have examined the existing data, recognize the 
problem as a problem, see the need for further research of the problem, and have already 
put forth effort to change and improve the way they practice.  The providers who are 
resistant to change to their practice habits may not see a need to research or contribute to 
research that studies the topic. 
Design Limitations 
The original intended sampling method was an identical mixed method sampling 




deep contemplation of the study limitations that the researcher recognized that the 
quantitative and qualitative data were not obtained using this type of sampling method.  
The quantitative data was obtained by evaluating all hematology admissions excluding 
BMT admissions for pathway criteria.  Therefore, the quantitative results reported are 
from all hematology admissions, including the patients who were admitted to the 
lymphoma and lymphoma/myeloma teams.  Only one of the properly documented/billed 
GOC discussions during October 2020 and January 2021 was authored by a leukemia 
hematologist, the others were completed by physicians from the lymphoma, myeloma, 
and supportive care teams.  Therefore, the scope of the problem specifically in leukemia 
hematologists is not accurately described.   While this does create a bias in the 
quantitative data, the effect on the qualitative study purpose is thought to be minimal.  
The qualitative inquiry is new research and considered to be the most useful component 
in promoting program success.  The study findings will be used to address the 
hematologists barriers by developing tailored implementation interventions guided by 
their educational needs.  Quantitative data is needed to formally evaluate all programs in 
the healthcare setting and was therefore necessary to be collected; however, in this case 
the data was used to more accurately describe a global problem that already exists in 
healthcare- implementation failure.   
Implications for Future Projects and/or Research 
Throughout the course of this scholarly inquiry, many system issues were 
uncovered that could benefit from further exploration.  The quantitative data shows lack 
of implementation success within the lymphoma and lymphoma/myeloma teams and 




and myeloma specialty hematologists.  Also, the contributory role of the APP to program 
implementation success or failure should be researched so that implementation endeavors 
are collaborative and successful.  In this case, the APP’s role evolved into one of the most 
influential factors of program success.  The APP is responsible for properly initiating the 
GOC pathway with a specific social work order in patients who meet the pathway 
criteria, yet 75% of the time there was a failure to do so; therefore, the APP barriers need 
to be researched in the future.  Another area of needed research involves the lack of 
integration of supportive and palliative care into hematology to determine where in the 
disease trajectory these services are best utilized and how the APP can promote 
collaboration within the two specialties.  Patients with hematologic malignancies rarely 
receive specialist palliative or hospice care and studies prospectively evaluating potential 
effects of integrated palliative care in these patients are rare (Oechsle, 2018).     
Implications for Practice 
 This study was an important first step towards understanding the barriers that 
hematologists possess surrounding GOC discussions.  As of September 2020, the success 
of the GOC pathway changed from desired to required when the ADCC implemented the 
IGCC initiative.  The ADCC is made up of America’s leading cancer centers and 
prioritizes protecting innovation, improving efficiencies, preserving quality-focused 
health policies, and measuring and setting standards for cancer care; being a part of the 
alliance’s pooled resources offers great benefit to each member institution.  The survival 
rates are 16% higher than community hospital centers and 8% better than academic 




participate in the initiative to improve quality and maintain the integrity of the 
organization’s positive reputation nation-wide.   
 Quality-focused health policy continues to evolve based on the newest evidence-
based facts.  But institutional culture and practice change is difficult to achieve.  The 
leaders, innovators, early adopters, and early majority must continue to develop education 
and programs based on the specific needs of the laggards and late majority.  APPs should 
exercise their influence in the healthcare social system as opinion leaders, change agents, 
and champions to better diffuse innovation.  The doctorly prepared APP possesses the 
ability to routinely incorporate and utilize theory, such as the diffusion of innovation 
theory (Rogers, 1962) in planning and implementing practice-changing quality initiatives 
and evaluating the success of these programs.   
Conclusion 
 This study aimed to describe and explore implementation of an institutional GOC 
pathway program, and hematologists barriers to having/documenting GOC discussions in 
relapsed high-risk leukemia patients.  The study confirmed suspicions that program 
participation was low and needed evaluated for improvement in implementation.  The 
almost absent number of properly documented GOC discussions warranted exploration of 
their barriers and offers valuable insight into the hematologist’s aversion to GOC 
discussions.  This information will be used for program evaluation with the CFIR, then 
incorporated into institutional efforts to achieve each of the four core components 
described in the IGCC initiative implementation planning guide.  The initiative was 




and how GOC conversations occur, and the implementation will occur over a three-year 
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Appendix A: Patient Support Screen  
Hello, 
Many patients tell us that being in the ICU can feel overwhelming, especially if you’re 
unsure about the next steps in your care and treatment. As part of your care, we meet with 
you and your family so that you can get up-to-date information about your condition and 
discuss any questions or concerns you have about your treatment.  
With any serious illness, it helps us to know what your values and goals are so that we 
can honor what’s important to you.  The information you share will enable us to know 
your wishes and best work together as a team.  
 
1. In case you are ever not able to speak for yourself, who do you want to make 
medical decisions for you?   
Type in name  
 
2. How is this person related to you?  
              □     Spouse 
              □     Partner 
              □     Parent 
              □     Child 
              □     Sibling 
              □     Friend 
              □     Other, explain 
3. Which statement is closest to your understanding of your present medical 
situation?  
□    Cure is very likely and is in the range of 76% to 100% for me 
□    Cure is likely and is in the range of 51% to 75% for me 
□    Cure is possible but not likely and is in the range of 26% -50% for me 
□    Cure is not at all likely and is in the range of 0-25% for me 
      The goal of treatment is to control the disease for as long as possible 




      The goal of treatment is to focus on   comfort, time with family and quality of 
life  
        
4. What is most important to you if your medical condition gets worse?  
              □     To live for as long as possible regardless of my medical condition  
              □     Continue treatment for a period of time but stop if there is no chance for a 
meaningful recovery 
              □     Continue treatment focused on quality of life and comfort only  
 
5. Right now, what is the most concerning to you?  
              □     Being able to communicate  
              □     Pain  
              □     Not getting better  
              □     How my family is coping             
 
6. What abilities are so critical to your life that you can’t imagine living without 
them?  
Check all that apply 
     □     Interacting with family and friends in a meaningful way 
            □     Performing daily living activities independently  
            □     Making my own decisions  
            □     Engaging in activities that bring me joy  
            □     Nothing is so critical that I cannot imagine living without 
 
7. Have you shared your health care wishes and goals with your family?  
               □   Yes 
              □   No 
8. Has the medical team explained your treatment plan in a way you can 
understand?   
□    Yes 





9. At this time, do you feel you are getting a consistent message from your 
doctors about your treatment plan?  
              □    Yes 





























Appendix B: Cover Letter 
 Hello again!    
I am very proud to announce that I am pursuing higher education and have chosen to 
incorporate my role in improving goal concordant care at COH into my scholarly 
research project.  Chart review of patients admitted to the Hematology/Hem transplant 
readmit service lines (excluding BMT) for the months of October 2020 and January 2021, 
indicated that ~30% of our inpatient admissions meet the criteria for consideration of 
inpatient GOC discussion.   
I would like to understand your perceived barriers to having/documenting GOC 
discussions.  Please be candid, this is an anonymous survey and participation is entirely 
voluntary.  Your answers will be compiled, analyzed, examined for trends, and included 
in my scholarly project final writing, which I plan to submit for publication once 
completed.   The findings will also be shared with you as we continue to implement the 
ADCC’s Improving Goal Concordant Care initiative at City of Hope!  Physicians, please 
click the link below to complete my short survey.  THANK YOU SO MUCH FOR 
YOUR SUPPORT! 
https://www.surveymonkey.com/r/LACYJO-DNP-GOC 
Consent is implied by voluntary completion of the survey.  Please see the attached 








Appendix C: SurveyMonkey Questionnaire 
1. In one sentence, please give your definition of a GOC conversation.  
2. Please describe your perceived barriers to having/documenting GOC 
conversations.  Examples may include thoughts surrounding prognostication, 
culture, effect on hope, comfort level with conversations, time constraints, or 
pressure to change the way you practice.   
